eFFECTOR Therapeutics, Inc.

EFTR

US28202V2079

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 19:14:38 11/07/2025 BST			5-day change	1st Jan Change
0.000200 ^USD	-50.00%		0.00%	0.00%

2024	Tyra Biosciences Names Doug Warner Chief Medical Officer	MT
2024	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from S&P TMI Index	CI

EFFECTOR Therapeutics to Shut Down Operations, Seeking Strategic Alternatives

Published on 24/06/2024 at 15:42, updated on 24/06/2024 at 15:44

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about eFFECTOR Therapeutics, Inc.

Tyra Biosciences Names Doug Warner Chief Medical Officer	10/09/24	MT
EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from S&P TMI Index	07/07/24	CI
EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index	01/07/24	CI
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	24/06/24	MT
Top Midday Decliners	24/06/24	MT
Sector Update: Health Care Stocks Advance Monday Afternoon	24/06/24	MT
EFFECTOR Therapeutics to Shut Down Operations, Seeking Strategic Alternatives	24/06/24	MT
EFFECTOR Therapeutics, Inc. Announces Cessation of Michael Byrnes, Chief Financial Officer	24/06/24	CI
Effector Therapeutics, Inc. Terminates Its Employees in Connection with the Planned Wind Down of the Company?s Operations	24/06/24	CI
Effector Therapeutics, Inc. Announces Director Resignations	24/06/24	CI
EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as CEO	24/06/24	CI
EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as President, Treasurer and Secretary, and Sole Member of the Board	24/06/24	CI
EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer	20/05/24	CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05/24	CI
Health Care Down on Retreat From Risk -- Health Care Roundup	04/04/24	DJ
Top Midday Decliners	04/04/24	MT
EFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	04/04/24	CI
Top Premarket Decliners	26/03/24	MT
EFFECTOR Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	25/03/24	CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	25/03/24	CI
EFFECTOR Therapeutics, Inc. - Special Call	15/03/24
EFFECTOR Therapeutics, Inc. - Special Call	24/01/24
EFFECTOR Therapeutics Says Study of Zotatifin in Breast Cancer Patients Yields 'Positive' Interim Data	08/12/23	MT
EFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients	08/12/23	CI
EFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer	28/11/23	CI

Chart eFFECTOR Therapeutics, Inc.

Duration

Period

EFTR: Dynamic Chart

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The Company uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Companyâs lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.

Employees

Sector

Biotechnology & Medical Research

More about the company